OncoSignal
Live from Open Targets Platform, fetched 2026-11-12 08:39 UTC. Every row links to its source record.

MECOM MDS1 and EVI1 complex locus

ENSG00000085276 · protein coding · Open Targets profile

[Isoform 1]: Functions as a transcriptional regulator binding to DNA sequences in the promoter region of target genes and regulating positively or negatively their expression. Oncogene which plays a role in development, cell proliferation and differentiation. May also play a role in apoptosis through regulation of the JNK and TGF-beta signaling. Involved in hematopoiesis. {ECO:0000269|PubMed:10856240, ECO:0000269|PubMed:11568182, ECO:0000269|PubMed:15897867, ECO:0000269|PubMed:16462766, ECO:0000269|PubMed:19767769, ECO:0000269|PubMed:9665135}.

In 12 of 15 cancers, the evidence for MECOM comes mainly from mutations found in tumours

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751prostate carcinomaprostate carcinomaprostate carcinoma: somatic 0.46prostate carcinoma: germline 0.64melanomamelanomamelanoma: somatic 0.55prostate adenocarcinomaprostate adenocarcinomaprostate adenocarcinoma: somatic 0.52pancreatic ductal adenocarcinomapancreatic ductal adenocarcinomapancreatic ductal adenocarcinoma: somatic 0.61lung carcinomalung carcinomalung carcinoma: somatic 0.61dyskeratosis congenitadyskeratosis congenitadyskeratosis congenita: germline 0.60nasopharyngeal neoplasmnasopharyngeal neoplasmnasopharyngeal neoplasm: germline 0.61esophageal adenocarcinomaesophageal adenocarcinomaesophageal adenocarcinoma: somatic 0.61kidney neoplasmkidney neoplasmkidney neoplasm: somatic 0.61lymphoid neoplasmlymphoid neoplasmlymphoid neoplasm: somatic 0.61cutaneous melanomacutaneous melanomacutaneous melanoma: somatic 0.61exocrine pancreatic carcinomaexocrine pancreatic carcinomaexocrine pancreatic carcinoma: somatic 0.61carcinoma of liver and intrahepatic bil…carcinoma of liver and intrahepatic biliary tractcarcinoma of liver and intrahepatic biliary tract: somatic 0.61skin carcinomaskin carcinomaskin carcinoma: somatic 0.61hepatobiliary neoplasmhepatobiliary neoplasmhepatobiliary neoplasm: somatic 0.61

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

PROTAC
UniProt Ubiquitination, Database Ubiquitination

gnomAD loss of function constraint: o/e 0.11180000007152557 (upper bound 0.17775000631809235). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of MECOM's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of MECOM's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.